Pharmaceutical Supply Chain Explained

Illustration of the pharmaceutical supply chain from a manufacturing plant to a warehouse and a pharmacy, with a temperature icon

Key takeaways

  • The pharmaceutical supply chain moves APIs and excipients to drug manufacturers, finished drugs to wholesale distributors, and then to pharmacies, hospitals and patients.

  • Money follows a separate route from the product: PBMs pay pharmacies for dispensed drugs and share manufacturer rebates with payers.

  • Third-party logistics providers store and move drugs without owning them, so ownership, payment and custody often sit with different parties.

  • CGMP, written storage and distribution procedures, DSCSA package-level tracing and labeled storage conditions follow the product through every handoff.

  • FDA counted four new drug shortages in 2025 but 93 ongoing ones at year end, tied to weak incentives for older products and limited capacity.

  • Mapping each node's owner, license check, tracing data, storage condition and handoff record shows which questions to put to a supplier or logistics provider.

The pharmaceutical supply chain moves active ingredients and excipients to drug manufacturers, then finished medicines to wholesalers, pharmacies, hospitals and patients. A second flow of payments, rebates and contracts runs beside it. Much of that money passes through a pharmacy benefit manager (PBM) and payers rather than through the companies that hold the product.

In the US, a few controls follow the product through every handoff. Current good manufacturing practice (CGMP) applies at the plant, and written procedures govern storage and distribution. Covered prescription drugs also carry Drug Supply Chain Security Act (DSCSA) tracing, and the label sets storage conditions.

Pharma supply chain management keeps those flows and controls lined up. The right lot should reach an authorized recipient and stay traceable if something goes wrong.

What is the pharmaceutical supply chain?

The pharmaceutical supply chain is the network of companies, facilities and contracts that turns raw materials into medicines for patients. The Department of Health and Human Services (HHS) maps its commercial part in a prescription drug flowchart with six parties. They are drug manufacturers, distributors, pharmacies, PBMs, payers and consumers.

That chart comes from the HHS Office of the Assistant Secretary for Planning and Evaluation (ASPE). In it, drugs travel one path, from manufacturer to distributor to pharmacy to consumer, while money and contracts take others.

ASPE's model starts at the finished drug, so it leaves out two groups that quality and logistics teams deal with daily. Upstream are the suppliers of active pharmaceutical ingredients (APIs), excipients, containers and closures. Alongside the main path are service providers who handle product without owning it. These include contract manufacturers, packagers, third-party logistics providers (3PLs), carriers and couriers.

Hospital pharmacies and clinics dispense drugs too, so read ASPE's chart as a map of the retail path rather than of every channel. The stretch from a released batch to the first carrier has its own Mercury guide on first-mile logistics in the pharmaceutical supply chain.

How does the pharmaceutical supply chain work?

Product moves through a series of handoffs, and each one can change who holds it, who owns it and which rule applies. The pharmaceutical supply chain process has four physical stages, plus a money flow with its own route. Each row below names the stage, its actors and the controls a partner there has to show.





Stage


Main actors

What moves

US controls that apply

Ingredient sourcing

API and excipient makers, component suppliers

APIs, excipients, containers, closures

API manufacturing guidance, plus testing and release of each component lot by the drug maker

Manufacturing and packaging

Drug manufacturers, contract manufacturers, packagers

Quarantined batches, then released finished packages

CGMP, quality unit release, DSCSA product identifier on each package

Wholesale distribution

Wholesale distributors, 3PLs, carriers

Cases and packages of finished drugs

State license and annual federal reporting, DSCSA transaction data, storage conditions

Dispensing

Retail and hospital pharmacies, clinics

Packages filled as prescriptions

DSCSA receipt checks and record keeping, state pharmacy licensing

Money and contracts

PBMs, payers, consumers

Rebates, payments, premiums, copays

Formulary, network and prime vendor agreements

Most controls travel with the package. The money flow, by contrast, runs on contracts between parties that may never see the product.

Ingredient sourcing

Every finished drug starts with an API. The Food and Drug Administration (FDA) describes APIs as the actual drugs that are then formulated into tablets, capsules and injections. FDA told Congress in 2019 that only 28% of facilities making APIs for the US market were in the United States. The other 72% were overseas and 13% were in China, a snapshot of FDA's facility data for August 2019.

API makers work to FDA's guidance on good manufacturing practice for active pharmaceutical ingredients, which describes good manufacturing practice (GMP) under a quality system. The drug maker then checks what arrives. Under FDA's CGMP rules, each lot of components, containers and closures is held until it has been sampled, tested or examined. The quality control unit then releases it for use.

Manufacturing and packaging

Manufacturers turn ingredients into finished, labeled packages under CGMP. FDA describes CGMP as minimum requirements for the methods, facilities and controls used in manufacturing, processing and packing. FDA reviews a manufacturer's CGMP compliance before it approves new and generic drug applications. Finished batches stay in quarantine until the quality control unit releases them.

For prescription drugs covered by the DSCSA, the manufacturer also puts a product identifier on each package. The law defines it as the standardized numerical identifier, lot number and expiration date. It appears in human-readable form and in a 2D data matrix barcode. Later partners use that package-level identity to verify and trace product.

Wholesale distribution and third-party logistics

Wholesale distributors sit between manufacturers and dispensers. In ASPE's chart, the distributor ships bulk drugs to pharmacies, pharmacies pay the distributor, and the distributor pays the manufacturer. A 3PL stores or moves product for a manufacturer, wholesaler or dispenser. Under the DSCSA definition, though, a 3PL does not take ownership of the product or direct its sale.

Wholesalers and 3PLs must be appropriately licensed and report licensure to FDA every year to count as authorized trading partners. A listing in FDA's reporting database does not mean FDA has licensed or approved the facility, so the state license still needs checking. On the manufacturer's side, written distribution procedures ship the oldest approved stock first, with temporary deviations allowed. They also record where each lot went, so it can be recalled.

Pharmacies, hospitals and the patient

Pharmacies, hospital pharmacies and clinics are the dispensers at the end of the physical chain. FDA's DSCSA page for pharmacists says pharmacies must only accept prescription drugs that are accompanied by product tracing documentation. They store that documentation for six years and quarantine and investigate suspect product. Tracing documentation stops at the counter, since it isn't required when a drug is dispensed to a patient.

Pharmacy licenses are a state matter, and the same FDA page sends pharmacists to state authorities to check them.

How money and contracts move

Money in the pharmaceutical supply chain doesn't follow the boxes. In ASPE's model, consumers pay premiums to payers and copayments to pharmacies, and the PBM pays pharmacies for dispensed drugs. Manufacturer rebates take a separate route, because the PBM shares them with payers.

The contracts explain the routes. Manufacturers hold formulary agreements with PBMs and distributor agreements with distributors. Pharmacies hold network agreements with PBMs and prime vendor agreements with distributors, and payers hold insurance contracts with consumers.

For a quality or logistics team, the lesson is that ownership, payment and custody don't always sit with one party. The owner of a shipment, the company paying for it and the 3PL or carrier holding it can all differ. Each handoff therefore needs a record of who held what, and when.

Controls that run across the chain

Five controls follow the product from the plant to the pharmacy counter. Each leaves a record that the next partner or an inspector can ask to see:

What is supply chain management in the pharmaceutical industry?

Pharmaceutical supply chain management means planning and controlling sourcing, production, inventory and distribution. Each lot should reach an authorized recipient in specification and stay traceable afterwards. It differs from supply chain work in most industries because many routine decisions are also regulatory obligations.

Several everyday tasks map straight onto the rules above. Supplier management includes incoming testing, because components can't be used until the quality unit releases them. Inventory rotation is a written procedure that ships the oldest approved stock first. Customer setup includes a license or registration check for each trading partner, and order records must let each lot be found for a recall.

Demand planning connects to shortage reporting. FDA says manufacturers provide FDA most drug shortage information. Its industry portal accepts notices of new discontinuances, GMP issues, demand increases, recalls and supply interruptions.

Vendors sell pharmaceutical supply chain solutions for each of these jobs. They include serialization and tracing software, temperature monitoring, licensed 3PL warehousing, and specialty courier and cold chain transport. A useful test for any of them is which record it produces and which requirement that record satisfies.

What challenges are present in the pharmaceutical supply chain?

Drug shortages, concentrated ingredient sourcing, illegitimate product and the exchange of tracing data between partners are the challenges FDA's own pages and reports document. Temperature control adds a physical risk on top.

New drug shortages have fallen sharply. FDA's drug shortage report to Congress for 2025 counts four new shortages in calendar year 2025, against a peak of 251 in 2011. FDA also says it worked with manufacturers to prevent 330 shortages that year.

The shortages that remain are harder to clear. As of December 31, 2025, FDA had identified 93 ongoing shortages tracked by its drug and biologics centers. The same report ties their persistence to weak incentives to make older, less profitable products and to limited manufacturing capacity.

FDA's 2019 task force report on drug shortage root causes and potential solutions named three root causes. The first was weak incentives to produce less profitable drugs. The second was a market that doesn't reward "mature quality systems". The third, closest to distribution and logistics work, was logistical and regulatory challenges that make recovery from a disruption difficult.

Concentrated sourcing adds exposure on top of those causes, as the 2019 API shares above show.

Illegitimate product is the risk the DSCSA targets. FDA's pharmacist guidance lists suspect drugs as possibly counterfeit, diverted, stolen, intentionally adulterated or unfit for distribution. Trading partners must notify FDA within 24 hours after determining that a product is illegitimate.

Tracing works only when every partner can send and receive the data. FDA has exempted small dispensers from certain DSCSA requirements until November 27, 2027, to give time to complete its small dispenser assessment. A small dispenser here is one whose company has 25 or fewer full-time pharmacists and pharmacy technicians.

Temperature-sensitive products can fail at any handoff where they wait outside a controlled space. Mercury's guide on preventing temperature excursions covers causes and controls. Second sources, buffer stock and backup lanes are sized in Mercury's guide to life science supply chain resilience.

Map your own chain before choosing partners

A one-page map of your own chain gives every later decision a reference point. For each product family, write down:

  1. Each node from API supplier to dispenser, and who owns, pays for and physically holds the product there.

  2. The license or registration you checked for each trading partner, and when you checked it.

  3. The tracing data that moves at each transfer, and the system that sends and receives it.

  4. The labeled storage condition, and how it is kept and recorded during storage and transport.

  5. The record that proves each handoff, who keeps it and for how long.

Gaps in that map are the questions to put to a supplier, distributor or logistics provider. For temperature-controlled lanes, Mercury ships clinical and commercial drugs for pharmaceutical manufacturers with GDP-aligned cold chain handling and full documentation.

Share on Linkedin
Share on X
Share on Facebook